Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Neutral Sphingomyelinase Blockade Enhances Hematopoietic Stem Cell Fitness Through an Integrated Stress Response

September 19, 2023

[Blood] Researchers demonstrated that pharmacologic and genetic inhibition of neutral sphingomyelinase-2 leads to sustained improvements in long-term competitive transplantation efficiency after ex vivo culture. Mechanistically, nSMase2 blockade activated a canonical integrated stress response and promoted metabolic quiescence in human and murine HSPCs.

Pd-1 Instructs a Tumor-Suppressive Metabolic Program That Restricts Glycolysis and Restrains Ap-1 Activity in T Cell Lymphoma

September 19, 2023

[Nature Cancer] Using tractable mouse models for T cell non-Hodgkin lymphomas and primary patient samples, investigators demonstrated that PD-1 signaling suppressed T cell malignancy by restricting glycolytic energy and acetyl coenzyme A production.

ABCC1 and Glutathione Metabolism Limit the Efficacy of Bcl-2 Inhibitors in Acute Myeloid Leukemia

September 19, 2023

[Nature Communications] Using CRISPR/Cas9 screening, researchers found that loss of ABCC1 strongly increased the sensitivity of AML cells to Venetoclax. Genetic and pharmacologic ABCC1 inactivation potentiated the anti-leukemic effects of BCL-2 inhibitors and efficiently re-sensitized Venetoclax-resistant leukemia cells.

Ppm1d Truncating Mutations Promote the Development of Genotoxic Stress-Induced Aml

September 19, 2023

[Leukemia] Using a transgenic mouse model, scientists demonstrated that truncated protein phosphatase magnesium-dependent 1 delta (PPM1D) reduced self-renewal of HSCs in basal conditions but promotes the development of aggressive AML after exposure to ionizing radiation.

CBFA2T3-GLIS2-Dependent Pediatric Acute Megakaryoblastic Leukemia Is Driven by GLIS2 and Sensitive to Navitoclax

September 19, 2023

[Cell Reports] Investigators described the development of CBFA2T3-GLIS2-driven mouse models of pediatric acute megakaryoblastic leukemia (AMKL) that recapitulated the phenotypic and transcriptional signatures of the human disease. They show that an activating Ras mutation that occurs in human AMKL increases the penetrance and decreases the latency of CBF2AT3-GLIS2-driven AMKL.

Physiological and Regenerative Functions of Sterile Alpha Motif Protein-14 in Hematopoiesis

September 19, 2023

[Experimental Hematology] Scientists generated a hematopoietic-specific conditional Samd14 knockout mouse model (Samd14-CKO) to study the role of Samd14 in hematopoiesis. The Samd14-CKO mouse was viable and exhibited no steady-state hematopoietic phenotype.

Synthesis and Anti-tumor Activities in Human Leukemia-Derived Cells of Polyenylpyrroles with a Methyl Group at the Conjugated Polyene Terminus

September 19, 2023

[Bioorganic & Medicinal Chemistry Letters] To develop novel drugs for treating T-cell acute lymphoblastic leukemia (T-ALL) and AML, a series of analogs having a polyenylpyrrole structure of natural compounds were synthesized and investigated their structure–activity relationships of in vitro anti-T-ALL and anti-AML activities.

Impact of Genetic Patterns on Sorafenib Efficacy in Patients with FLT3-Itd Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center, Cohort Study

September 19, 2023

[Signal Transduction And Targeted Therapy] Scientists explored the efficacy of sorafenib therapy in this population with different concomitant genetic patterns. In a multi-center, cohort study, they enrolled patients with FLT3-ITD AML undergoing allogeneic hematopoietic cell transplantation.

Clonal Hematopoiesis – A Novel Entity That Modifies Pathological Processes in Elderly

September 19, 2023

[Cell Death Discovery] The authors review recent advancements in the field of clonal hematopoiesis and how it may affect the disease’s development in old age.

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for Kt-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-cell Lymphoma and...

September 19, 2023

[Kymera Therapeutics, Inc.] Kymera Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T cell Lymphoma and R/R Peripheral T cell Lymphoma.

Axicabtagene Ciloleucel in Large B Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation: The Phase II Alycante Trial

September 18, 2023

[Nature Medicine] Investigators conducted a Phase II study (ALYCANTE) to assess the efficacy and safety of a single axi-cel infusion as a second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma deemed ineligible for ASCT but eligible for CAR-T cell therapy.

Notch and Retinoic Acid Signals Regulate Macrophage Formation from Endocardium Downstream of Nkx2-5

September 11, 2023

[Nature Communications] Researchers identified the regulatory network of endocardial hematopoiesis. In vivo and ex vivo analyses validated that the Nkx2-5-Notch axis was essential for the generation of both hemogenic and cushion endocardial cells, and the suppression of retinoic acid signaling via Dhrs3 expression played important roles in further differentiation into macrophages.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.